bluuebunny/crossref_metadata_2025_split huggingface dataset:
Protective effect of Cyclo(His‐Pro) on peritoneal fibrosis through regulation of HDAC3 expression
Authors: Kim Ji Eun , Han Dohyun , Kim Kyu Hong , Seo Areum , Moon Jong Joo , Jeong Jin Seon , Kim Ji Hye , Kang Eunjeong , Bae Eunjin , Kim Yong Chul , Lee Jae Wook , Cha Ran‐hui , Kim Dong Ki , Oh Kook‐Hwan , Kim Yon Su , Jung Hoe‐Yune , Yang Seung Hee 
Published: July 2024

AbstractPeritoneal dialysis is a common treatment for end‐stage renal disease, but complications often force its discontinuation. Preventive treatments for peritoneal inflammation and fibrosis are currently lacking. Cyclo(His‐Pro) (CHP), a naturally occurring cyclic dipeptide, has demonstrated protective effects in various fibrotic diseases, yet its potential role in peritoneal fibrosis (PF) remains uncertain. In a mouse model of induced PF, CHP was administered, and quantitative proteomic analysis using liquid chromatography–tandem mass spectrometry was employed to identify PF‐related protein signaling pathways. The results were further validated using human primary cultured mesothelial cells. This analysis revealed the involvement of histone deacetylase 3 (HDAC3) in the PF signaling pathway. CHP administration effectively mitigated PF in both peritoneal tissue and human primary cultured mesothelial cells, concurrently regulating fibrosis‐related markers and HDAC3 expression. Moreover, CHP enhanced the expression of nuclear factor erythroid 2‐related factor 2 (Nrf2) while suppressing forkhead box protein M1 (FOXM1), known to inhibit Nrf2 transcription through its interaction with HDAC3. CHP also displayed an impact on spleen myeloid‐derived suppressor cells, suggesting an immunomodulatory effect. Notably, CHP improved mitochondrial function in peritoneal tissue, resulting in increased mitochondrial membrane potential and adenosine triphosphate production. This study suggests that CHP can significantly prevent PF in peritoneal dialysis patients by modulating HDAC3 expression and associated signaling pathways, reducing fibrosis and inflammation markers, and improving mitochondrial function.
Decreasing Premedication for Blood Transfusions: A Quality Improvement Project
Authors: Hole Ashley , Budhai Alexandra , King Kerry , Borge P. Dayand 
Published: July 2024

ABSTRACT

Background:
Premedication administration to patients who are to receive blood transfusions continues despite evidence of a lack of benefit when given to prevent febrile nonhemolytic or mild allergic transfusion reactions. Reviews of ordering practices and staff surveys on an adult inpatient hematology–oncology unit in our multisite oncology medical center indicated a lack of standardization and overuse of premedication in blood transfusions and a lack of knowledge of when it was appropriate to use premedication.

Methods:
A literature search was performed, and the evidence led to a proposal for a quality improvement (QI) project focused on development of an evidence-based algorithm to guide clinicians in when to administer which premedication, development of clear documentation for premedication plans, integration of the documented premedication plans into electronic orders for blood products, and staff education. Interventions included a hospital-wide algorithm and an electronic order to be integrated with a premedication plan for each patient on the adult hematology–oncology unit.

Results:
Seven months after implementation of the intervention, premedication use among patients decreased by 57.6%, and the transfusion reaction rate decreased from 1% to 0.8%. Staff knowledge as measured by responses to pre- and postintervention surveys on the appropriate use of premedication also improved.

Conclusion:
Evidence-based interventions can reduce the incidence of premedication use in patients receiving blood transfusions.
Original Research: The Lived Experiences of Nurses as Patients: A Qualitative Study
Authors: Kimchi-Woods Judith , Pugh Robin , Wiley Molly 
Published: July 2024

ABSTRACT

Background:
An ED admission and hospitalization are scary experiences for anyone, and potentially more so for nurses. Yet there is scant information about nurses as patients in the nursing research literature. This likely reflects a general tendency among researchers to study the needs of patients but not those of nurses.

Objective:
This qualitative phenomenological study sought to explore the lived experiences of nurses who were admitted as patients to a hospital directly from an ED.

Methods:
A sample of nurse patients 21 years of age and older and including various genders, nursing specialties, and diagnoses were recruited using maximum variation purposive sampling. A semistructured interview guide was created, and data were collected through individual interviews conducted either face-to-face or via telephone. Data were coded manually, and thematic analysis was conducted using Dedoose software.

Results:
The analysis revealed that many participants had experienced tremendous undue stress during their hospitalization. Four themes were identified: to tell or not to tell, pulling the nurse card, taking one's care into one's own hands, and having to make medical decisions while sick.

Conclusions:
The study findings indicate that nurses who are hospitalized have different needs than do hospitalized individuals in the lay population. The findings inform our recommendations, which health care organizations, nurse educators, and nurse leaders can use to promote smoother, more compassionate care for nurse patients. Staff nurses can use them to better prepare themselves for caring for a nurse patient—or becoming one. The study findings can also serve to guide future research.
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation
Authors: Zhang Liangjun , Xie Pingfan , Li Mingqiao , Zhang Xiaoxun , Fei Shuke , Zhao Nan , Li Ling , Xie Qiaoling , Xu Ziqian , Tang Wan , Zhu Guanyu , Zhu Zhixian , Xu Zuzhi , Li Jianwei , Zhang Chengcheng , Boyer James L. , Chen Wensheng , Cai Shi-Ying , Pan Qiong , Chai Jin 
Published: July 2024

Background and Aims:
Inflammatory response is crucial for bile acid (BA)-induced cholestatic liver injury, but molecular mechanisms remain to be elucidated. Solute Carrier Family 35 Member C1 (SLC35C1) can transport Guanosine diphosphate-fucose into the Golgi to facilitate protein glycosylation. Its mutation leads to the deficiency of leukocyte adhesion and enhances inflammation in humans. However, little is known about its role in liver diseases.

Approach and Results:
Hepatic SLC35C1 mRNA transcripts and protein expression were significantly increased in patients with obstructive cholestasis and mouse models of cholestasis. Immunofluorescence revealed that the upregulated SLC35C1 expression mainly occurred in hepatocytes. Liver-specific ablation of Slc35c1 (Slc35c1 cKO) significantly aggravated liver injury in mouse models of cholestasis induced by bile duct ligation and 1% cholic acid–feeding, evidenced by increased liver necrosis, inflammation, fibrosis, and bile ductular proliferation. The Slc35c1 cKO increased hepatic chemokine Ccl2 and Cxcl2 expression and T cell, neutrophil, and F4/80 macrophage infiltration but did not affect the levels of serum and liver BA in mouse models of cholestasis. Liquid chromatography with tandem mass spectrometry analysis revealed that hepatic Slc35c1 deficiency substantially reduced the fucosylation of cell-cell adhesion protein CEACAM1 at N153. Mechanistically, cholestatic levels of conjugated BAs stimulated SLC35C1 expression by activating the STAT3 signaling to facilitate CEACAM1 fucosylation at N153, and deficiency in the fucosylation of CEACAM1 at N135 enhanced the BA-stimulated CCL2 and CXCL2 mRNA expression in primary mouse hepatocytes and Primary Liver Carcinoma/Poliomyelitis Research Foundation/5-ASBT cells.

Conclusions:
Elevated hepatic SLC35C1 expression attenuates cholestatic liver injury by enhancing CEACAM1 fucosylation to suppress CCL2 and CXCL2 expression and liver inflammation.
Indications and Outcomes of Emergency Keratoplasty in a Major New Zealand Eye Tertiary Referral Center, 2000 to 2021
Authors: Al-Mahrouqi Haitham , Lewis James S. , Crawford Alexandra Z. , McGhee Charles N. J. 
Published: July 2024

Purpose:
To report the indications and outcomes of emergency keratoplasty over a 21-year period in Greenlane Clinical Centre, the major tertiary eye referral center in Auckland, New Zealand (Aotearoa).

Methods:
A retrospective review of medical records of all emergency keratoplasties performed in Greenlane Clinical Centre from January 2000 to September 2021 was conducted. Demographic, preoperative, intraoperative, and 1-year postoperative data were collected.

Results:
Emergency keratoplasty was performed in 102 eyes of 97 patients (54 men), comprising 5.6% of transplants performed (N = 1830) in this period. The mean age was 53 years (range = 4–95 years, SD = 20). Patients of Māori ethnicity were overrepresented (31%). Corneal perforation was present in 90% of eyes, and microbial keratitis was the most common indication. Bacteria were the most commonly isolated organisms (38%). The mean preoperative and 12-month postoperative best potential corrected distance visual acuity was 1.6 and 1.2 (logMAR), respectively. All cases of therapeutic keratoplasty achieved initial therapeutic success, with no eyes lost or requiring repeat emergency keratoplasty. Complications included nonhealing epithelial defects (19%), cataract (19%), glaucoma (15%), allograft rejection (13%), and corneal melting (5%). Fifteen cases (15%) had documented graft failure at 12 months. Multivariate analysis revealed that younger age was the only statistically significant factor associated with failure at 12 months.

Conclusions:
Emergency keratoplasty was the indication for 5.6% of keratoplasties performed. Our results compare favorably with those in the literature, possibly because of early intervention and lower incidence of fungal keratitis. The reported overrepresentation of Māori has important implications for health access and delivery in New Zealand.
Bone and Joint Infections in Children With Sickle Cell Disease in French Guiana: A 13-Year Retrospective Multicenter Review
Authors: Furgier Apolline , Goutines Juliette , Dobian Succes , Zappa Magaly , Demar Magalie , Aigoun Nadjia , Oubda Bruno , Faye Albert , Elenga Narcisse , Osei Lindsay 
Published: July 2024

Introduction:
Sickle cell disease (SCD) is a genetic disorder with a high infectious morbidity and mortality and a heterogeneous distribution in France. One of the challenges is to differentiate a bone and joint infection (BJI) from a vaso-occlusive crisis. This challenge is particularly prevalent in French Guiana, an overseas territory with the highest incidence of SCD in France. The aim of this study was to describe the epidemiology of BJI in children with SCD in French Guiana.

Method:
This was a retrospective multicentric descriptive study of SCD patients living in French Guiana aged under 18 and diagnosed with a BJI between 2010 and 2022. These BJI were divided into 2 groups: those with microbiological documentation (d-BJI) and those without microbiological identification (ud-BJI).

Results:
A total of 53 episodes of BJI in 42 patients (mean age 7.2 years) were reported. Clinical symptoms on arrival were comparable between the d-BJI and ud-BJI groups. Patients in the d-BJI group had longer average hospital stays (40.4 days vs. 16.8 days, P = 0.01) and Salmonella spp. were the most identified bacteria (n = 8/13). White blood cell count was greater in the d-BJI group (30.3 G/L vs. 18.G/L, P = 0.01) and a collection was more frequently identified on imaging (11/13 vs. 16/40, P = 0.01) in this group. Initial in-hospital antibiotic therapy was longer in the d-BJI group (17.2 days vs. 12.8, P = 0.02), as were infection-related complications (9/13 vs. 12/40 P = 0.01).

Conclusion:
BJI in children with SCD is not sufficiently microbiologically documented. Progress must be made to improve the documentation of BJI.
Differential Serum Phosphate Levels in Pediatric Febrile Syndromes and Their Clinical Significance
Authors: Milman Yonatan , Landau Daniel , Lebel Asaf , Levinsky Yoel , Marcus Nufar , Chezana Adi , Ashkenazi-Hoffnung Liat 
Published: July 2024

Background:
The potential of hypophosphatemia (HP) to differentiate between febrile syndromes and its clinical significance in children without sepsis were not previously described.

Methods:
Data were retrospectively collected of febrile children 3 months to 18 years of age, hospitalized at general pediatric wards during 2010–2019. Phosphate levels were compared between bacterial infection (BI), viral infection (VI), and Kawasaki disease (KD). Regression analyses were used to evaluate the relationship between HP and outcome.

Results:
Of 3963 febrile children, 559 had BI, 3271 had VI, and 133 had KD. In BI compared to VI and KD, HP was more prevalent (49.2%, 19.7%, and 31.6%, respectively; P<0.001) and more severe [median (interquartile range) phosphate standard deviation score: −1.85 (2.08), −0.56 (2.08), and −1.20 (2.28), respectively; P<0.001]. In the BI group, Pi-SDS level was lower among patients with than without bacteremia (−2.33 ± 1.8 vs. –0.79 ± 1.68; P<0.001). Phosphate levels displayed discriminatory potential between bacterial and viral etiologies, with an area under the curve of 0.719 (95% CI, 0.697–0.742). Minimal phosphate standard deviation score values had a negative weak correlation with the maximal C-reactive protein levels and white blood cell count. Univariate and multivariate analyses showed an association of HP with a more severe disease course, manifested by longer hospital stay [+2.10 (95% CI, 0.75–3.46) days; P=0.003] and a higher rate of intensive care unit admission [odds ratio, 2.63 (95% CI, 1.94–3.56); P<0.001).

Conclusions:
Hypophosphatemia rates were highest in bacterial etiology, intermediate in KD, and lowest in viral etiology and were associated with poorer outcomes. Phosphate level may serve as a marker for ruling out a bacterial etiology.
Nucleus accumbens myocyte enhancer factor 2C mediates the maintenance of peripheral nerve injury–induced physiological and behavioral maladaptations
Authors: Serafini Randal A. , Farzinpour Zahra , Patel Vishwendra , Kelley Abigail M. , Estill Molly , Pryce Kerri D. , Sakloth Farhana , Teague Collin D. , Torres-Berrio Angelica , Nestler Eric J. , Shen Li , Akbarian Schahram , Karkhanis Anushree N. , Blitzer Robert D. , Zachariou Venetia 
Published: July 2024

Abstract
Preclinical and clinical work has demonstrated altered plasticity and activity in the nucleus accumbens (NAc) under chronic pain states, highlighting critical therapeutic avenues for the management of chronic pain conditions. In this study, we demonstrate that myocyte enhancer factor 2C (MEF2C), a master regulator of neuronal activity and plasticity, is repressed in NAc neurons after prolonged spared nerve injury (SNI). Viral-mediated overexpression of Mef2c in NAc neurons partially ameliorated sensory hypersensitivity and emotional behaviors in mice with SNI, while also altering transcriptional pathways associated with synaptic signaling. Mef2c overexpression also reversed SNI-induced potentiation of phasic dopamine release and neuronal hyperexcitability in the NAc. Transcriptional changes induced by Mef2c overexpression were different than those observed after desipramine treatment, suggesting a mechanism of action different from antidepressants. Overall, we show that interventions in MEF2C-regulated mechanisms in the NAc are sufficient to disrupt the maintenance of chronic pain states, providing potential new treatment avenues for neuropathic pain.
Tyrosine Kinase-2 Inhibitor (Deucravacitinib) for Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Authors: Mahmoud Abdelrahman , Ahmed Ali A. S. , Naeem Ahmed , Abuelazm Mohamed , Elshinawy Mahmoud , Hassan Abdul Rhman , Rezq Hazem , Abdelazeem Basel 
Published: July 2024

Objective:
Deucravacitinib is a tyrosine kinase-2 inhibitor that shows promise as an emerging treatment option for psoriasis. We aimed to evaluate the efficacy and safety of different doses of deucravacitinib vs. placebo or apremilast on psoriasis treatment.

Methods:
We performed a systematic review and pairwise and network meta-analyses of randomized controlled trials published in Web of Science, SCOPUS, EMBASE, PubMed, and Cochrane Central databases from the inception of databases until March 31, 2023. We used the risk ratio for dichotomous outcomes, and the mean difference with corresponding 95% confidence interval for continuous outcomes. We registered our protocol in PROSPERO (ID: CRD42023413976).

Results:
We analyzed 4 randomized controlled trials involving 2,156 patients randomly assigned to receive placebo, 60 mg of apremilast once daily, or various doses of deucravacitinib (3 mg every other day, 3 mg once daily, 3 mg twice daily, 6 mg twice daily, or 12 mg once daily). Deucravacitinib achieved significantly better outcomes compared with placebo across multiple efficacy measures, including the Psoriasis Area and Severity Index score (P < 0.01), Static Physician’s Global Assessment score (P < 0.01), Psoriasis Symptoms and Signs Diary score (P < 0.01), Dermatology Life Quality Index score (P < 0.01), and scalp-specific Physician’s Global Assessment score (P < 0.01). When comparing 3 mg of deucravacitinib twice daily with 60 mg of apremilast once daily, deucravacitinib exhibited superior outcomes in terms of the Psoriasis Area and Severity Index (P < 0.01), Dermatology Life Quality Index (P < 0.01), Static Physician’s Global Assessment (P < 0.01), and scalp-specific Physician’s Global Assessment scores (P < 0.01). Deucravacitinib and apremilast were associated with a higher incidence of adverse events compared with placebo, including diarrhea, nausea, headache, and infections. However, no significant differences were observed between interventions regarding serious adverse events or adverse events leading to discontinuation.

Conclusion:
Deucravacitinib and apremilast show promising efficacy as psoriasis treatments. While adverse events were more common with these treatments compared with placebo, the incidence of serious adverse events did not significantly differ between the intervention and placebo groups.
Development of Data Quality Indicators for Improving Hospital International Classification of Diseases–Coded Health Data Quality Globally
Authors: Otero-Varela Lucía , Sandhu Namneet , Walker Robin L. , Southern Danielle A. , Quan Hude , Eastwood Cathy A. 
Published: July 2024

Background:
Hospital inpatient data, coded using the International Classification of Diseases (ICD), is widely used to monitor diseases, allocate resources and funding, and evaluate patient outcomes. As such, hospital data quality should be measured before use; however, currently, there is no standard and international approach to assess ICD-coded data quality.

Objective:
To develop a standardized method for assessing hospital ICD-coded data quality that could be applied across countries: Data quality indicators (DQIs).

Research Design:
To identify a set of candidate DQIs, we performed an environmental scan, reviewing gray and academic literature on data quality frameworks and existing methods to assess data quality. Indicators from the literature were then appraised and selected through a 3-round Delphi process. The first round involved face-to-face group and individual meetings for idea generation, while the second and third rounds were conducted remotely to collect online ratings. Final DQIs were selected based on the panelists’ quantitative and qualitative feedback.

Subjects:
Participants included international experts with expertise in administrative health data, data quality, and ICD coding.

Results:
The resulting 24 DQIs encompass 5 dimensions of data quality: relevance, accuracy and reliability; comparability and coherence; timeliness; and Accessibility and clarity. These will help stakeholders (eg, World Health Organization) to assess hospital data quality using the same standard across countries and highlight areas in need of improvement.

Conclusions:
This novel area of research will facilitate international comparisons of ICD-coded data quality and be valuable to future studies and initiatives aimed at improving hospital administrative data quality.
The Potential Clinical Benefits of Direct Surgical Transgastric Pancreatic Necrosectomy for Patients With Infected Necrotizing Pancreatitis
Authors: Timmerhuis Hester C. , Ngongoni Rejoice F. , Li Amy , McGuire Sean P. , Lewellen Kyle A. , Dua Monica M. , Chughtai Komal , Zyromski Nicholas J. , Visser Brendan C. 
Published: July 2024

Objective
Surgical transgastric pancreatic necrosectomy (STGN) has the potential to overcome the shortcomings (ie, repeat interventions, prolonged hospitalization) of the step-up approach for infected necrotizing pancreatitis. We aimed to determine the outcomes of STGN for infected necrotizing pancreatitis.

Materials and Methods
This observational cohort study included adult patients who underwent STGN for infected necrosis at two centers from 2008 to 2022. Patients with a procedure for pancreatic necrosis before STGN were excluded. Primary outcomes included mortality, length of hospital and intensive care unit (ICU) stay, new-onset organ failure, repeat interventions, pancreatic fistulas, readmissions, and time to episode closure.

Results
Forty-three patients underwent STGN at a median of 48 days (interquartile range [IQR] 32–70) after disease onset. Mortality rate was 7% (n = 3). After STGN, the median length of hospital was 8 days (IQR 6–17), 23 patients (53.5%) required ICU admission (2 days [IQR 1–7]), and new-onset organ failure occurred in 8 patients (18.6%). Three patients (7%) required a reintervention, 1 (2.3%) developed a pancreatic fistula, and 11 (25.6%) were readmitted. The median time to episode closure was 11 days (IQR 6–22).

Conclusions
STGN allows for treatment of retrogastric infected necrosis in one procedure and with rapid episode resolution. With these advantages and few pancreatic fistulas, direct STGN challenges the step-up approach.
Metabolic Tumor Volume on 18-Fluorodeoxyglucose Positron Emission Tomography as a Prognostic Marker of Survival in Patients With Locally Advanced or Metastatic Neuroendocrine Neoplasms Treated With 177Lutetium-DOTA-Octreotate Peptide Receptor Radionuclide Therapy
Authors: De Silva Madhawa K. , Chan David L.H. , Bernard Elizabeth J. , Conner Alice J. , Mascall Sophie L. , Bailey Dale L. , Roach Paul J. , Clarke Stephen J. , Diakos Connie I. , Pavlakis Nick , Schembri Geoff 
Published: July 2024

Objective
We investigated metabolic tumor volume (MTV) and total lesion glycolysis (TLG) on pre-treatment FDG-PET as prognostic markers for survival in patients with metastatic neuroendocrine neoplasms (NENs) receiving peptide receptor radionuclide therapy (PRRT).

Methods
A retrospective review of patients with metastatic NENs receiving PRRT was undertaken. Pre-treatment FDG-PET images were analyzed and variables collected included MTV and TLG (dichotomized by median into high vs low). Main Outcomes were overall survival (OS) and progression-free survival (PFS) by MTV and TLG (high vs low).

Results
One hundred five patients were included. Median age was 64 years (50% male). Main primary NEN sites were small bowel (43.8%) and pancreas (40.0%). Median MTV was 3.8 mL and median TLG was 19.9. Dichotomization formed identical cohorts regardless of whether MTV or TLG were used. Median OS was 72 months; OS did not differ based on MTV/TLG high versus low (47.4 months vs not reached; hazard ratio, 0.43; 95% confidence interval [CI], 0.18–1.04; P = 0.0594). Median PFS was 30.4 months; PFS differed based on MTV/TLG high versus low (21.6 months vs 45.7 months; hazard ratio, 0.35; 95% CI, 0.19–0.64; P = 0.007).

Conclusions
Low MTV/TLG on pre-treatment FDG-PET was associated with longer PFS in metastatic NEN patients receiving PRRT.